Article
Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine.
Blood - 30 Apr 2009
Höglund Andreas, Nilsson Lisa M, Forshell Linus Plym, Maclean Kirsteen H, Nilsson Jonas A
Abstract excerpt
Decitabine (also referred to as 5-aza-2'-deoxycytidine) is a drug that has recently been approved by the Food and Drug Administration (FDA) for the treatment of myelodysplastic syndrome (MDS). The mechanism of action is believed to be the blocking of DNA methylation and thereby reactivating silenced genes involved in harnessing MDS. When analyzing reactivation of genes involved in Burkitt lymphoma (BL), we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.